source
- Lilly reports early positive results for new JAK2 inhibitor in hard-to-treat myelofibrosisLilly has incorporated a JAK2‑targeting drug originally discovered by Ajax Therapeutics after its recent acquisition. The experimental pill is intended for patients with myelofibrosis, a difficult‑…
- Celiac disease faces new therapeutic possibilities as companies target underlying inflammationCeliac disease affects roughly one in every hundred people worldwide, imposing a daily burden that goes far beyond dietary restrictions. Currently, patients have no approved medicines and must rel…